
We’re excited to announce that we’ve acquired @ars_pharma Nectin-4 antibody. The #antibody will be used to further develop a differentiated Nectin-4 #ADC, using our proprietary #LinkerTechnology, as we broaden our ADC pipeline. Read more here: https://t.co/ShitBQjyTS















